Study details
Enrolling now
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Baylor College of Medicine
NCT IDNCT01853631ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
64
Study length
about 22 years
Ages
≤75
Locations
2 sites in TX
About this study
This trial is testing a new treatment for people with advanced B-cell Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic lymphocytic leukemia. The treatment involves modifying T cells to target cancer cells more effectively. This is a Phase 1 trial.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells
- 2.Take Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
PhasePhase 1
Routeinjection
Primary goalNumber of patients with dose limiting toxicity (DLT)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
injection, intravenous
Endpoints
Primary: Number of patients with dose limiting toxicity (DLT)
Body systems
Oncology